Alaunos Therapeutics Inc (TCRT) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators suggest the stock is overbought, and there are no significant trading trends, news catalysts, or positive financial performance to support a buy decision. Additionally, there are no proprietary trading signals or recent influential trading activity to justify immediate action.

Technical Analysis

The MACD histogram is positive and expanding, suggesting bullish momentum. However, the RSI is at 86.278, indicating the stock is overbought. Moving averages are converging, and the pre-market price is at the R1 resistance level of 3.15, which may limit further upside in the short term.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

NULL. No recent news, significant insider or hedge fund activity, or congress trading data. The MACD indicates bullish momentum, but this is countered by overbought RSI levels.

Neutral/Negative Catalysts

The stock is overbought based on RSI. Financial performance remains weak with negative net income and declining EPS. No significant trading trends or news catalysts to drive the stock higher.

Financial Performance

In Q3 2025, revenue remained at 0 with no growth YoY. Net income improved slightly by 2.84% YoY but remains negative at -1,159,000. EPS dropped by 24.29% YoY to -0.53. Gross margin is at 100%, but this is not indicative of profitability given the lack of revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast TCRT stock price to rise

Buy

Hold

Sell

Current: 3.190

Low

Averages

High